This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Sector Weekly Rewind

BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that was Oct. 11, 2010:

Pfizer (PFE) buys King Pharmaceuticals (KG) for $3.6 billion to bolster its pain drug franchise.

Pfizer adds new partners through King Buy

Alkermes (ALKS) CEO Richard Pops (@popsalks) breaks company news on Twitter. Bravo! (via @MikeHuckman)

The news broken by Pops: Finally, a drug approval in October! Alkermes received FDA clearance to market Vivitrol as a treatment for opioid addiction.

Alexza Pharmaceuticals (ALXA) and Jazz Pharmaceuticals (JAZZ) not as lucky: FDA denies approval to both of their drugs.

Questcor Pharmaceuticals (QCOR) receives belated FDA approval for Acthar as a treatment for infantile spasms.

The week's top-performing sector stocks: Pharmathene (PIP) (+120%), Molecular Insight Pharmaceuticals (MIPI) (+65%), Rosetta Genomics (ROSG) (+60%), SIGA Technologies (SIGA) (+56%) and King Pharmaceuticals (KG) (+37%).

Johnson & Johnson's (JNJ) abiraterone boosts survival by four months for patients with advanced prostate cancer.

Seattle Genetics (SGEN) reported a second clinical trial win for the lymphoma drug brentuximab vedotin.

This week's Biotech Stock Mailbag: Exact Sciences (EXAS), Sequenom (SQNM), Vanda Pharmaceuticals (VNDA), Delcath Systems (DCTH), Labopharm (DDSS), Cadence Pharmaceuticals (CADX) and Transcept Pharmaceuticals (TSPT).

Forbes' Matt Herper on the fight against drug-resistant germs.

Cancer drug analyst and blogger Sally Church spends the week at the European cancer conference known as ESMO.

The week's worst-performing sector stocks: Alexza Pharmaceuticals (ALXA) (-56%), Spherix (SPEX) (-24%), AspenBio Pharma (APPY) (-17%), Anadys Pharmaceuticals (ANDS) (-16%) and ProPhase Labs (PRPH) (-13%).

Cubist Pharmaceuticals (CBST) reports third quarter Cubicin sales of $154 million, lower than the consensus estimate of $162 million. The company reports higher-than-expected earnings for the quarter on lower operating expenses.

The biggest (sore) losers: Arena Pharmaceuticals (ARNA) investors.

Chemist and blogger Derek Lowe takes another skeptical look at the anti-aging claims made about GlaxoSmithKline's resveratrol.

Will the withdrawal of Meridia help or hurt other weight-loss pills? (via Pharmalot)

Reuters Health editor Ivan Oransky on Geron (GERN) and its first-ever stem cell study in patients with spinal cord injury.

"Scrapers" are scouring web sites looking for patients' personal information.

Roche reports weaker-than-expected sales of its three most important drugs -- Avastin, Rituxan and Herceptin. Overall, third quarter revenue fell 7%.

ImmunoGen (IMGN) and Novartis (NVS) strike a licensing deal to develop cancer drugs based on ImmunoGen's "armed antibody" drug delivery technology.

Exelixis (EXEL) licenses two experimental cancer drugs to Bristol-Myers Squibb (BMY).

Perfect FDA Drug Approval Pickers

Halozyme Therapeutics (HALO) cut 25% of its workforce in a restructuring move.

The week in financings: Regeneron Pharmaceuticals (RGEN) ($175 million), Cytori Therapeutics (CYTX) ($19 million) and Anadys Pharmaceuticals (ANDS) ($25 million).

FDA doesn't always heed the recommendations offered by its advisory panels. (via @matthewherper)

Phase III data on Titan Pharmaceuticals' (TTNP.OB) implantable addiction drug is published in JAMA.

Boehringer Ingelheim drops development of a drug for the controversial disorder known as female sexual dysfunction.

Celgene (CELG) completes acquisition of Abraxis BioScience.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,139.80 -32.88 -0.19%
S&P 500 1,992.04 -2.25 -0.11%
NASDAQ 4,525.6780 -2.0110 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs